Serabiotics

Serabiotics is a Madrid-based biotech spin-off from Caltech, founded in 2015, that leverages its proprietary platform for isolating components from human plasma to create advanced tools for cell biology and assisted reproduction. The company's primary focus is on non-therapeutic applications, including developing embryo culture supplements, cell culture supplements, and specialized in vitro assays. It operates as a B2B developer and supplier, collaborating with pharmaceutical companies and research institutions to enhance embryo development, implantation research, and cell culture expansion. Serabiotics is positioned in the high-growth markets of IVF and cell therapy, offering enabling technologies rather than direct therapeutics.

Proprietary methods for isolating and purifying specific components from human plasma, including growth factors, cytokines, and extracellular matrix proteins, to create advanced 3D matrices and supplements for cell and embryo culture.

Serabiotics competes with large life science reagent companies (e.g., Thermo Fisher, Merck) that offer standardized cell culture media and supplements, as well as specialized IVF media companies. Its differentiation lies in its specific expertise in human plasma fractionation for non-therapeutic, matrix-based applications.